Rekover Therapeutics
Rekover Therapeutics is developing therapies for repair of tissue damage caused by multiple sclerosis. Our lead drug is a first-in-class, phase 2 ready molecule, with compelling preclinical data in two animal disease models and an excellent clinical safety profile. Rekover Therapeutics has assembled an experienced team with proven MS drug development credentials and deep expertise in the biology of remyelination. Patents are filed in key global territories protecting the technology. The company has short timelines and limited spend to proof of concept, with multiple strategic options following the POC study which is ready to operationalise in near COVID-19 free Australia and NZ
7-day free trial · no credit card
Verified contacts
1
available on Kipplo
LinkedIn employees
2
1 to 10 range
Open roles
—
no listings
Distinct roles
1
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 1 verified contacts at Rekover Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
1 contacts with verified email or phone · masked until revealed.
Showing 1 of 1 verified contacts
Top roles at Rekover Therapeutics
1 distinct titles indexed · top 1 shown.
- 1director
Sign up to unlock all 1 contacts at Rekover Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 1 verified contacts at Rekover Therapeutics
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.